All authors: Section of Critical Care Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
Pediatr Crit Care Med. 2018 Dec;19(12):1130-1136. doi: 10.1097/PCC.0000000000001738.
High Vasoactive-Inotropic Scores have demonstrated association with poor outcomes in pediatric cardiac ICUs and are being calculated more frequently in studies of critically ill noncardiac patients. Available studies differ in their approach to assigning Vasoactive-Inotropic Scores, making direct comparisons difficult. The goal of this investigation is to compare multiple approaches to Vasoactive-Inotropic Score assignment to determine their strength of association with mortality in a general pediatric intensive care population. In doing so, we aim to help validate the use of the Vasoactive-Inotropic Score in noncardiac patients and to help inform future studies of the relative strength of available approaches in assigning this score.
Retrospective chart review.
PICU at an academic freestanding children's hospital.
Two-thousand seven-hundred fifty-two consecutive patients admitted over a 17-month time period were screened for receiving inotrope or vasopressor therapies regardless of disease process. Four-hundred seventy-four patients met inclusion criteria.
None.
For each patient treated with continuous infusions of vasoactive medications, a Vasoactive-Inotropic Score was calculated (and then recalculated) every time they had a documented dose change. Multiple strategies were evaluated to generate receiver operating characteristic curves in relation to mortality. Area under the curve was greatest when evaluating the maximum Vasoactive-Inotropic Score (Max Any) during the initial treatment course (0.788) with an increasing relative risk as the score increased. The Vasoactive-Inotropic Score at 48 hours after treatment initiation had next highest area under the curve (0.736). Primary diagnosis categories were also analyzed, and area under the curve was greatest for the cardiovascular group (0.879).
Increasing Vasoactive-Inotropic Scores for patients in the PICU are associated with mortality risk. The scoring strategy used can influence the strength of the association, as can the primary diagnosis category.
高血管活性-正性肌力评分已被证明与儿科心脏重症监护病房患者的不良预后相关,并且在危重症非心脏患者的研究中更频繁地计算。可用的研究在分配血管活性-正性肌力评分的方法上存在差异,使得直接比较变得困难。本研究的目的是比较多种血管活性-正性肌力评分分配方法,以确定它们与一般儿科重症监护人群死亡率的关联强度。这样做,我们旨在帮助验证血管活性-正性肌力评分在非心脏患者中的使用,并帮助告知未来研究中分配该评分的可用方法的相对强度。
回顾性图表审查。
学术型独立儿童医院的 PICU。
在 17 个月的时间内,筛选了 2752 名连续入院的患者,无论疾病过程如何,都接受了正性肌力或血管加压药物治疗。474 名患者符合纳入标准。
无。
对于每例接受持续输注血管活性药物治疗的患者,每次记录剂量变化时都会计算(然后重新计算)血管活性-正性肌力评分。评估了多种策略来生成与死亡率相关的接受者操作特征曲线。在初始治疗过程中评估最大血管活性-正性肌力评分(Max Any)时,曲线下面积最大(0.788),评分增加时相对风险增加。治疗开始后 48 小时的血管活性-正性肌力评分曲线下面积次之(0.736)。还分析了主要诊断类别,心血管组的曲线下面积最大(0.879)。
儿科重症监护病房患者的血管活性-正性肌力评分增加与死亡风险相关。使用的评分策略会影响关联的强度,主要诊断类别也是如此。